News

Incanthera plc is pleased to confirm that, at a meeting of Warrant Holders held today, both resolutions put to the meeting in respect of the extension to the duration and exercise price of the warrants were passed.

Accordingly, the terms of the warrants issued in conjunction with the fundraising announced on 23 March 2021, have been amended such that they now expire on 12 April 2024 and have an exercise price of 10p.

For further enquiries:

Incanthera plc

www.incanthera.com

Tim McCarthy, Chairman

+44 (0) 7831 675747
tim.mccarthy@incanthera.com

Simon Ward, Chief Executive Officer

+44 (0) 7747 625506
simon.ward@incanthera.com

Suzanne Brocks, Head of Communications 

+44 (0) 7776 234600
suzanne.brocks@incanthera.com

AQSE Corporate Adviser: 
Cairn Financial Advisers LLP 
Jo Turner/Ludo Lazzaretti

+44 (0) 20 7213 0880 

Broker:
Stanford Capital Partners Ltd
Patrick Claridge/Tom Price/John Howes/Bob Pountney

+44 (0) 20 3650 3650

Notes to Editors

Incanthera is dedicated to innovative technologies in dermatology and oncology. It seeks to identify and commercialise inspirational therapeutics combined with uniquely targeted delivery systems, for innovative solutions to clinical, commercially relevant unmet needs.

The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. The Company is currently focussed upon delivering Sol to a commercial partner.

Originating from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford, the Company has acquired and developed a portfolio of specific cancer-targeting therapeutics, with a strategy to develop each candidate from initial acquisition/discovery to commercially valuable partnerships at the earliest opportunity in its development pathway.

For more information on the Company please visit: www.incanthera.com